Antimicrobial resistance (AMR) is a global health threat, especially in low-/middle-income countries 30 (LMICs), where there is limited surveillance to inform empiric antibiotic treatment guidelines. 31
Introduction 47
correlates for national antibiotic exposures 6,7 in the case of human gut metagenomes, or as an 69 approach to monitoring global AMR in the case of sewage 8 . However, to our knowledge, no study to 70 date has used taxonomic and resistome profiles of pooled metagenomes to directly estimate the AMR 71 prevalence in clinical isolates within the same population, across a range of species and antimicrobial 72 classes. This approach would enable intermittent, strategic sampling of a subset of individuals in a 73 population to estimate the burden of AMR in clinical isolates, facilitating evidence-based 74 development of empiric treatment guidelines without the need for isolate-based microbiological 75
surveillance. Most samples taken to assay colonisation (e.g. faeces/rectal swabs, nasal/throat swabs) 76 are relatively non-invasive and acceptable for individuals, and tolerated by particularly vulnerable 77 groups, such as neonates. 78
79
The concept of a taxonomy-adjusted AMR metric or AMR resistance potential for a metagenome has 80 been described previously 6,9 as the average metagenome fraction encoding resistance genes for a 81 particular antibiotic or antibiotic group, across all bacteria in a sample that can potentially carry such 82 resistance genes, based on known taxonomic ranges for the resistance gene families. To model the 83 benefit of such a metric in predicting resistance in clinical isolates within a population, we took 84 pooled faecal samples from a sub-population of individuals (>100) in three disparate geographic 85 settings with varying AMR prevalence, namely Cambodia, Kenya and the United Kingdom (UK), and 86 validated the model predictions using microbiological data from clinical isolates processed by 87 laboratories in these locations over a seven-year period (2010) (2011) (2012) (2013) (2014) (2015) (2016) (2017) . 
Samples and Settings 92
Faecal material stored in three existing biobanks was chosen for study; ethical approval for the 93 broader use of these samples was in place. Samples comprised: (i) rectal swabs from children aged 1-94 59 months with and without malnutrition, taken on admission to Kilifi County Hospital in Kilifi, 95
Kenya, from 1 st April to 30 th September 2016, and stored in Amies transport media + 1ml phosphate 96 buffered saline at -80°C ("Pharmacokinetics of Antimicrobials and Carriage of Antimicrobial 97
Resistance amongst Hospitalised Children with Severe Acute Malnutrition (FLACSAM)' study 10 98
[KEMRI/SERU/CGMR-C/023/3161; OXTREC 47-15]); (ii) faecal samples taken from newborns on 99 admission to Angkor Hospital for Children in Siem Reap, Cambodia, from 11 th September 2013 to 100 10 th September 2014, and stored in tryptone soya broth + 10% glycerol at -80°C 11 Human Genetics, Oxford, UK. For each study site, we created a "population pool", which consisted of 147 the pooling of equimolar concentrations of all extracts from that setting with ≥1ng DNA/μl. To 148 validate our pooling approach, we also created one smaller pool in each setting, a so-called "30- 
Sequence Data Processing 169
We determined the taxonomic abundance of bacterial species and resistance genes at individual and 170 pooled sample levels using a recently developed bioinformatics pipeline 26 . This pipeline incorporated 171 established approaches to taxonomic profiling, and an adapted approach to quantify resistance gene 172 markers present in a metagenome (for details of the method, see 26 ). Briefly, the sequenced paired-end 173 reads were quality-filtered based on PHRED scores (≥ Q25 and ≥ 50 bp), and adapters removed using 174 (v.37.72) at 100% sequence identity. The number of sequences that mapped to each resistance gene 182
were subsequently corrected to remove resistance gene length bias. This was done using four metrics, 183 namely (1) specific read count (number of sequences that map exclusively to the resistance gene); (2) 184 specific lateral coverage (proportion of the resistance gene covered by sequences mapping exclusively 185 to the gene); (3) resistance gene length; and (4) and average read length (average length of reads that 186 mapped to the resistance gene), and by the following formula: corrected gene count (CGC) = (specific 187 read count x average read length) / (resistance gene length x specific lateral coverage). 188
189
The CARD database attempts to classify each resistance gene variant by its association with AMR. To 190 be included in CARD, an AMR determinant must be described in a peer-reviewed scientific 191 publication, have its DNA sequence available in GenBank, and include clear experimental evidence of 192 elevated MIC over controls 31 . We used these data to map and aggregate counts of resistance 193 genes/variants associated with resistance to a specific antibiotic. In the process, we ranked the 194 resistance genes/variants into two categories, reflecting to some extent the public health risks posed 33 , 195 and thereby creating two sets of antibiotic resistance gene metrics. The first (AMRDEF; Supplementary  196 Data 1), included only AMR determinants with the "Confers_Resistance_to_Antibiotic" relationship 197 ontology term, whereby the gene associated with demonstrably elevated MIC is known to confer or 198 contribute to clinically relevant resistance to a specific antibiotic drug 31 . The second (AMRALL; 199 Supplementary Data 2), contained corrected counts of all resistance genes with clear experimental 200 evidence of increasing the MIC, including those associated with clinically relevant resistance (as for 201 AMRDEF), plus those without the "Confers_Resistance_to_Antibiotic" relationship ontology term. For 202 the purposes of this study we have used the term "resistance gene" to define any relevant genetic 203 marker of resistance, including genes that confer resistance by mutation (but can have a susceptible 204 wild type), and genes that confer resistance through presence/absence. 205 206
Validation of Pooling 207
We evaluated to what extent pooled resistome data was a non-biased representation of the individual 208 resistomes making up the pool. Resistance gene abundances of the 30-sample pools and individually 209 sequenced samples were converted to relative abundances, such that gene abundances in each sample 210 summed to one. Then, for each of the three different settings, individual samples were used to 211 compute the empirical distribution of each gene by repeated random sampling of its relative gene 212 abundance out of the individual samples (bootstrapping with n=100,000 repeats). We were then able 213 to compare the pool abundance of each gene with its empirical distribution in the same setting 214 (within-setting comparison) and in the other two settings (across-setting comparison). We computed 215 the fraction of resistance genes for which the pool estimate was within 90% central quantile of the 216 empirical distribution. The resulting metric was restricted between 0 (i.e. 0% of resistance genes in 217 the pool were as expected given the individual resistomes) and 1 (i.e. 100% of resistance genes in the 218 pool were as expected). Because bootstrapping of gene abundances relies on having a sufficient 219 number of samples with non-zero abundance, we limited our analysis to genes present in ≥50% of all 220 
Taxonomy Adjusted Resistance Potential Metrics 228
We developed several candidate metrics of resistant infection risk, based on pool metagenomic data 229 on resistance gene abundance and bacterial species composition, and evaluated their potential to 230 accurately predict the likelihood of antibiotic resistant invasive infections in a population. We refer to 231 these as 'taxonomy-adjusted resistance potential (RP)' metrics, which consisted of two parameters. 232
The first parameter, RCGC, was given through the sum of corrected gene counts (CGC) of variants 233 associated with resistance to a given antibiotic, j (RCGCj) divided by the total CGC of all resistance 234 genes in the pool. RCGC,j was calculated based on either variants with experimental evidence of 235 increasing the MIC (AMRALL) or only variants known to confer clinically relevant resistance 236 (AMRDEF). The second parameter, RTax, was given through the estimated abundance of a clinically 237 relevant bacterial grouping (derived from Bracken estimates) divided by the total estimated 238 abundance of bacterial taxa in the pool. The bacterial groupings tested were the Enterobacterales 239 order, Enterobacteriaceae family, and the grouping of the four most common and clinically relevant 240 bacterial genera/species within the Enterobacteriaceae family across sites (namely Escherichia coli, 241
Klebsiella pneumoniae, Salmonella spp, Enterobacter spp). 242 243
Bayesian Modelling 244
With each taxonomy-adjusted RP, we fitted a Bayesian generalized linear model to the data and 245 applied model comparison. This allowed us to assess the potential of the different metrics to predict 246 observed antibiotic resistance amongst clinical invasive Enterobacterales isolates. We used de-247 duplicated counts of isolates (unique bacterial species per antibiogram and patient-ID) for the 248 analyses. We let i denote the setting (Cambodia, Kenya or UK), and j the antibiotic (see below for a 249 list). We assumed that counts of resistant samples follow a binomial distribution. Our model then 250 predicts the count of resistance (ri,j) among tested Enterobacterales isolates (ni,j) using a probability of 251 resistance (pi,j), which is modelled as 252
The model intercept ( ) is specific for each antibiotic (j) but not setting (i), representing a baseline 257 propensity of resistance for any given antibiotic. Because resistance propensities can vary widely 258 between different antibiotics. We assume independent baselines (fixed effects). The setting-specific 259 information is RTax,i, which gives information about pathogen levels in setting i, as well as RCGC,i,j, 260 which carries information about resistance toward antibiotic j in setting i. For β1,j and β2,j, the 261 predictive effects of RCGC and RTax, we assumed these to represent the clinical ecology of resistance 262 genes so that they are specific to each antibiotic, j, but not to each setting, i. We further assumed that 263 different antibiotics have different but related β-values (variable effects, specified below). We 264 included only those antibiotics that had existing antibiotic susceptibility test (AST) data in at least two 265 out of three settings (trimethoprim-sulfamethoxazole, nitrofurantoin, nalidixic acid, meropenem, 266 imipenem, gentamicin, ciprofloxacin, chloramphenicol, cefuroxime, ceftriaxone, ceftazidime, 267 cefpodoxime, cefoxitin, cefotaxime, ampicillin, amikacin); missing observations were excluded from 268 the likelihood evaluation. We fitted the above model with RCGC being either AMRDEF or AMRALL and 269
with RTax being either of the three bacterial groupings discussed earlier, yielding a total of six separate 270 model fits. Due to the limited number of infection isolates with AST results (especially in Cambodia), 271
we chose standard weakly informative priors for the intercept and the effect parameters. In addition, 272
we restricted the effect of gene abundance to be positive, reflecting our view that only a positive 273 association of resistance genes and clinical resistance is biologically reasonable. We therefore chose The best taxonomy-adjusted RP metric was selected using Bayesian leave-one-out cross validation 35 288 which estimates a model's pointwise out of sample prediction accuracy. The prediction accuracies are 289 then used to directly compare all models using stacking weights 36 . In brief, models with smaller cross-290 validation errors (e.g. smaller prediction errors), get more weight relative to other models in the model 291 comparison. We also included in the comparison two models with RCGC (either AMRDEF or AMRALL), 292
following Equation (1) The study included 210 admission samples from Kenya, 200 from the UK and 153 from Cambodia 304 (n=154 -1 rejected sample), totalling 563 samples for metagenomic analysis (Fig 1) . In addition, 76 305 follow-up samples were taken from 37/154 newborns in Cambodia during their inpatient stay or upon 306 hospital discharge for a separate project; these were processed alongside the study samples (Fig 1) . 307
We only considered DNA extracts with yields ≥1ng/ul (79-89% of samples; Fig 1) , and 19 DNA 308 extracts from the separate longitudinal study were included in the Cambodia population pool due to 309 processing error. In total, population pools in Kenya, the UK and Cambodia, comprised 177, 157, and 310 156 pooled sample extracts. Thirty high DNA-yield samples (≥9ng/ul) from each setting were used 311 for the validation study, as well as being included in the population pools. To prevent bias, potential 312 associations between high-yield samples and population traits were ruled out in advance. The total 313
Gbp of data obtained per population pool were 51.6 (Kenya), 55.1 (UK) and 52.6 (Cambodia). The We identified 863 different antimicrobial resistance genes across any sample or pool (Cambodia: 684; 321 Kenya = 527; UK = 520), which were proven to increase the MIC for 163 antimicrobials (AMRALL) 322 and known to confer clinically relevant resistance for 113 antimicrobials (AMRDEF). The number of 323 resistance genes identified in population pools was largest in Cambodia (n=490), followed by the UK 324 each setting is given in Fig 2. Enterobacterales were the main bacterial taxa identified from population 331 pools in the UK (75.7%) and Cambodia (69.7%) but not in Kenya (32.4%) (Fig 2A) . Within the 332
Enterobacterales, >95% of the bacteria were from the Enterobacteriaceae family in all settings (UK: 333 96.3%; Cambodia: 99.4%; Kenya: 99.1%). The predominant species within the Enterobacterales order 334 in population pools were E. coli and K. pneumoniae, followed by Enterobacter spp. (Fig 2E) . These 335 species and genera combined accounted for 92.4% of all Enterobacterales taxa in Kenya, 88.5% in the 336 UK and 88.1% in Cambodia. The abundance of E. coli, was >20-fold higher than that of K. 337 pneumoniae in population pools from the UK (E. coli: 63.2%; K. pneumoniae: 2.2%) and Kenya (E. 338 coli: 28.4%; K. pneumoniae: 1.3%). In contrast both species had similar abundance in the Cambodia 339 population pool (E. coli: 30%; K. pneumoniae: 26.9%). Enterobacter spp. abundance was also higher 340 in Cambodia (4.5%) compared to the UK (1.6%) or Kenya (0.2%). The remaining Enterobacterales 341 comprised other genera, each being <2% of the total bacterial taxa in the three settings ( Fig 2G) . 342
Infections by Enterobacterales accounted for approximately a third of all blood and cerebrospinal 343
fluid infections in the three settings (Kenya: 36.8%; Cambodia: 33.0%; UK: 28.2%) ( Fig 2B) . Similar 344 to the findings from population pools, most of these Enterobacterales infections involved the 345 Enterobacteriaceae family (UK: 91.2%, Cambodia: 89.2%; Kenya: 91.8%; Fig 2B) . Likewise, the 346 predominant Enterobacterales species in all settings were E. coli and K. pneumoniae, with the 347 proportion of E. coli infections being at least double that of K. pneumoniae in the UK (E. coli: 16.1%; 348 K. pneumoniae: 4.8%) and Kenya (E. coli: 13.8%; K. pneumoniae: 5.9%), but not in Cambodia (E. 349 coli: 13.7%; K. pneumoniae: 11.7%) ( Fig 2F) . Enterobacter spp. was the next most common 350
Enterobacterales genus in all settings (Cambodia: 3.1%; Kenya: 2.7%; UK: 2.2%), but the remaining 351
Enterobacterales species and genera accounted for <2% of the total invasive infections by any 352 bacterial order each in all three settings ( Fig 2H) . A notable exception was Salmonella spp., which 353 accounted for 9.9% of the total infections in Kenya (therefore also included in Fig 2F and the 354 equivalent plot for population pools [Fig 2E] ). Details of all invasive infections by bacteria other than 355 the Enterobacterales are given in Supplementary Fig 1. 
365
The highest relative abundances of resistance genes observed in each setting were for genes 366 associated with resistance to aminoglycosides, amphenicols, fluoroquinolones, tetracyclines and 367 macrolides (48.1%, 45.8% and 43.6% of the total counts in Cambodia, Kenya and the UK 368 respectively) ( Fig 3A, left-hand or antibiotic sub-classes (e.g. 1 st generation cephalosporins), the highest relative abundances were 376 observed for erythromycin (Cambodia: 3.9%; Kenya: 4.2%; UK: 4.4%) and chloramphenicol 377 (Cambodia: 3.6%; Kenya: 3.5%; UK: 4.2%) in all settings (Fig 3A, right-hand panel) . That for 378 resistance genes to antibiotics other than those listed was 76% (Cambodia), 76.5% (Kenya) and 76.1% 379 (UK) (data not shown). The relative abundance of resistance genes for all other single 380 antibiotics/antibiotic sub-classes was <2% in all settings, except for tigecycline (Cambodia: 2.8%; 381 Kenya and UK: 2.2%) and clindamycin (Kenya: 2.1%; UK: 2.6%). Resistance prevalence in 382
Enterobacterales isolates causing blood and cerebrospinal fluid infections is displayed in Fig.3B  383 (right-hand panel) for the 16 antibiotics with antibiotic susceptibility test data in ≥2 settings. For 384 comparison, this is shown alongside the relative abundance of resistance genes for the same 385 antibiotics in population pools (Fig.3B, left-hand panel) . Model predictions were made for 16 antibiotics, which were those that had antibiotic susceptibility 443 test (AST) data for Enterobacterales isolates causing infection in at least two of the three settings 444 (Supplementary Data 5). Our best model accurately predicted the number of resistant infections in the 445 target populations for 100% of antibiotics with AST data in Kenya (12/12) and UK (14/14). In 446 Cambodia, the model accurately predicted the counts of resistant infections for 75% of antibiotics 447 (9/12). Compared to this, the baseline model did not correctly predict 50% of antibiotics across the 448 three settings (19/38). We computed the mean-squared errors of the mean model predictions relative 449 to the observations. The baseline model had an error of 468, whilst the final model ( Fig 5) had an 450 error of 33. 
466
Bayesian model predictions expressed as percentages are shown in Supplementary Fig 2 for  467 antibiotics where AST results were available from > 100 invasive infection isolates. Above this 468 threshold, predicted percentage resistance was accurate for 100% of antibiotics (14/14 with >100 469 tested isolates). 470
471
Discussion 472
473
In this study we have demonstrated the feasibility of a novel, pragmatic approach to surveillance of 474 bacterial antimicrobial resistance of relevance to human infection, with a focus on Enterobacterales as 475 one of the major bacterial resistance threats 38, 39 . Our results show that metagenomic analysis of pooled 476 faecal material (pooled at equimolar concentrations) is effective at predicting invasive infections 477 caused by Enterobacterales resistant to in-use antibiotics in a population, across a range of different 478 age groups and geographic settings. Our approach would enable intermittent, acceptable and relatively 479 non-invasive sampling of a small number of individuals within a population (e.g. 100-200), with the 480 advantage that a single centralised infrastructure (either in-country or internationally) could undertake 481 the metagenomic sequencing and analysis. This can be done independently of development of a 482 network of classical microbiological laboratories in multiple settings, which can be resource-intensive 483 in terms of capital and running costs, and is not feasible in the short-term, especially in LMICs, which 484 frequently have the highest AMR burden. 485
486
Based solely on pool size and sequencing depth (50-55Gbp/pool), we developed predictive metrics 487 (RP) without the need for costly and labour-intensive multiplexing of samples (i.e. individually 488 identifying samples in the pool by means of barcoded sequences) or selective sequencing approaches 489 based on enrichment for predefined panels of resistance genes. Unlike other AMR gene profiling 490 approaches our bioinformatics pipeline (ResPipe) incorporates the capacity to identify both specific 491 AMR gene variants (e.g. such as blaCTX-M-33 versus blaCTX-M-63), as well as being able to aggregate by 492 gene family. This is especially important for the prediction of phenotypes, as genes that differ by only 493 single nucleotides/amino acids can have distinct phenotypic spectra. Pooled metagenomes/resistomes 494 were also found to be an accurate, non-biased representation of the individual sample 495 metagenomes/resistomes. Population pools comprising rectal swabs with as little as ≥1ng/ul 496 DNA/sample were found to be sufficient to derive RP metrics with predictive value; this is useful in 497 terms of optimizing the sample processing workflows. Finally, in producing relatively deeply 498 sequenced (50-55Gbp/metagenome) and complete (i.e. not restricted to 16S) metagenomes on 90 499 individuals, we have also made a significant contribution to the human microbiomics data repository, 500 freely available for other researchers to use for study. 501
502
The limitations of our approach were most obvious for the neonatal group from Cambodia, where 503 predicted resistance matched the observed resistance in invasive isolates for 75% of antibiotics 504 compared to 100% of antibiotics in Kenya and the UK. One explanation for this might be that the 505 population pool for this group was found to have included 19 longitudinal samples (12% of all 506 samples in the pool) collected from individuals during their hospital inpatient stay, potentially biasing 507 the metagenomics profile of population pools and infection metadata designed to reflect community 508 (i.e. non-hospital) profiles. Rapid changes in the neonatal resistome occur following exposure to the 509 hospital environment 40 . Analyses of neonatal metagenomes have shown that these are predisposed to 510 rapid flux, and in hospital typically reflect the environmental hospital "microbiome" 41 . Cambodia was 511 also the only setting where the age group considered for metagenomics analysis (i.e. neonates), did 512 not correspond exactly with the available infection metadata analysed (i.e. infants up to 90 days of 513 age), which may also have influenced the accuracy of our predictive approach. Our analysis was also 514 limited by the scarce antibiotic susceptibility test (AST) results available for invasive infection 515 isolates, particularly in Cambodia, where the maximum number of isolates with AST results for any 516
given antibiotic was 65, compared to 324 in Kenya and 912 in UK. The smaller number of isolates 517 from Cambodia meant that the model fit contained less information to accurately predict resistance in 518 this setting. Moreover, AST results were only available for a limited number of antibiotics across all 519 three settings, and ideally AST approaches used for comparison would have been standardised across 520 the settings. Finally, our analyses are heavily dependent on the robustness of the reference gene 521 database, and the accuracy of genotypic-phenotypic correlations catalogued therein. In general, 522 however, we would expect this knowledge base to become increasingly robust, thus strengthening our 523 predictions. This may explain why in this study, a model that considers all gene variants with 524 experimental evidence of increasing the minimum inhibitory concentration (MIC), outperformed a 525 model considering only genes known to confer clinically relevant resistance. 526 527 Further studies to validate our promising proof-of-principle observations in additional settings across 528 age categories, especially the neonatal group, are warranted. There is potential to extend the approach 529 to consider other priority bacterial groups and different colonisation samples. For example, pools 530 could be extended to include samples from nasopharyngeal sites, where other potential pathogens 531 predominate (e.g. Streptococcus spp., Staphylococcus spp.). To develop the most rapid, convenient, 532 simple and inexpensive method possible, future studies should also consider further simplifications to 533 the method such as whether the same accurate predictions can be generated by pooling all samples 534 prior to DNA extraction and then performing the extraction only once. Further work should also test 535 the resolution of the approach to characterise and track local/sub-national variation in AMR 536 prevalence, or in community versus healthcare-associated contexts. A mathematical framework for 537 minimum-cost implementation of pooled-sample metagenomics-based surveys to quantify the burden 538 of resistance in new settings without prior microbiology or AST data would also be of benefit, and 539 could be greatly informed by the data we have generated, which can contribute to simulation work 540 addressing pools sizes, pool numbers per region, and sequencing depth. 541
542
We conclude that surveillance based on population colonisation metagenomics and taxonomy-543 adjusted AMR metrics presented here are in principle a valuable public health opportunity, and may 544 represent an alternative or bridging measure to the implementation of local and regional laboratory-545 based infrastructures focussed on culturing isolates from clinical specimens, especially in resource-546 limited settings. This novel approach could be used to overcome the current paucity of quality AMR 547 surveillance data and inform setting-tailored rationalization of/or access to antibiotics, context-548 appropriate treatment guidelines, organized measures to prevent AMR and ultimately public-health 549 decision in conjunction with relevant stakeholders, especially in LMICs. The raw sequence data reported in this study have been deposited in the European Nucleotide Archive 562 under accession number PRJEB34871. The code to extract CARD data, that required to generate the 563 final datasets and analyses, plus any required input files, are available from the ResPipe GitLab 564 repository (https://gitlab.com/hsgweon/ResPipe); ResPipe output data can be found at the ResPipe 565
Gitlab subdirectory (https://gitlab.com/hsgweon/ResPipe/tree/master/data). 566 567
